Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
NRF2 in Amyotrophic Lateral Sclerosis ALS is the most common motor neuron disease in adults and estimates have reported that 31,000 patients live with ALS in the US, where on average 5,000 new patients are diagnosed annually (Mehta et al., 2023)
Moreover, in a double-blind, randomized, placebo-controlled trial enrolling 1200 patients, survival to hospital discharge was 40 days in the Gln-supplementation group versus 38 days in the placebo group
That screening is the difference a physician-led setting makes
Published 2019 Oct 14
US$ 23.45
US$ 29.55
US$ 23.05
